MorphoSys(MOR) - 2022 Q4 - Annual Report

Annual Report 2022 Our Clinical Pipeline | Clinical Programs Developed | | --- | | by Partners (Selection) | | | Most advanced | | | --- | --- | --- | | | development stage | | | | | LAUNCH | | Program Indication | | | | Tafasitamab L-MIND / Relapsed or refractory (r/r) | .. 02 . | | | diffuse large B-cell lymphoma (DLBCL) | | | | frontMIND / First-line DLBCL | . . . O | | | inMIND / r/r follicular lymphoma/ | ... O | | | marginal zone lymphoma | | | | B-MIND / r/r DLBCL | ... O | | | firstMIND / First-line ...